Dr Reddy's settles Clarinex suit with Schering/Sepracor

Indian generic major Dr Reddy's Laboratories has entered into agreements with Nasdaq-listed Sepracor and fellow US firm Schering Corp, allowing  it to manufacture a generic version of several different formulations of  hay fever drug Clarinex (desloratadine).

Schering and Sepracor which will grant Dr Reddy's rights to manufacture  and market generic versions of the Clarinex-D-12 Hour and Clarinex-D-24  Hour products, with six months marketing exclusivity, and the Clarinex  REDITABS product, with six months marketing co-exclusivity, starting in  2012. Dr Reddy's will also market a generic version of the Clarinex 5mg  tablet six months after the launch of the first generic version of that  product.

The agreements resolve all pending patent infringement actions filed by  Schering and Sepracor against Dr Reddy's in the US District Court for  the District of New Jersey.